-
Inozyme Pharma NASDAQ:INZY Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through our in-depth understanding of the biological pathways involved in mineralization, company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. Inozyme is initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.
Location: | Website: www.inozyme.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
192M
Cash
144.5M
Avg Qtr Burn
-21.39M
Short % of Float
9.17%
Insider Ownership
0.52%
Institutional Own.
97.79%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INZ-701 (ENPP1-Fc) Pediatric Details ENPP1 deficiency, Genetic disorder, Rare genetic disease | Phase 3 Data readout | |
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease, ABCC6 Deficiency | Phase 1/2 Update | |
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease | Phase 1b Data readout | |
INZ-701 (ENPP1-Fc) Details End-stage renal disease | Phase 1 Data readout |